{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-006544","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2025-01-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.839407+00:00","generated_at":"2026-05-27T08:17:54.196708+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sirexatamab + chemo/bev shows 35% ORR in CRC (vs 23% control); gastric trial fails to advance to Phase 3","bullets":["Part B DeFianCe (n=188): sirexatamab arm ORR 35% vs control 23%; DCR 86% vs 84%.","Left-sided tumors ORR 38% (experimental) vs 25% (control); DKK1-high upper quartile ORR 48% vs 11%.","PFS not yet mature; 82 patients still on study. Leap plans registrational Phase 3 in CRC subject to regulatory discussions.","Part C DisTinGuish gastric: no clear positive signal; primary PFS endpoints will be negative; no Phase 3 plans for gastric.","Gastric study showed high discordance between investigator and BICR; sirexatamab combo well-tolerated in both studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-006544","json":"https://secwatch.observer/filing/0001104659-25-006544.json","markdown":"https://secwatch.observer/filing/0001104659-25-006544.md","text":"https://secwatch.observer/filing/0001104659-25-006544.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925006544/0001104659-25-006544-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465925006544/tm254560d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T08:17:54.196708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}